Changes in Indices of Steatosis and Fibrosis in Liver Grafts of Living Donors After Weight Reduction

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 May 20

PMID 35592121

Authors

Jaehyuk Choi

YoungRok Choi

Su Young Hong

Sanggyun Suh

Kwangpyo Hong

Eui Soo Han

Jeong-Moo Lee

Suk Kyun Hong

Nam-Joon Yi

Kwang-Woong Lee

Kyung-Suk Suh

Affiliations

Soon will be listed here.

Abstract

Background: A short-term weight reduction program for potential living donors was introduced to reduce the extent of hepatic steatosis prior to liver transplantation. We aimed to investigate changes in non-invasive hepatic steatosis and fibrosis indices among those who completed the program.

Methods: Among 1,950 potential living liver donors between January 2011 and May 2019, 160 living donors joined the weight reduction program. The prospectively collected clinical data of these potential liver donors were analyzed retrospectively. Hepatic steatosis and fibrosis scores were determined using the fatty liver index (FLI), hepatic steatosis index (HSI), and NAFLD fibrosis score (NFS) and compared to MR spectroscopy (MRS) fat fraction results before and after weight reduction.

Results: Thirty-nine potential living donors who had undergone MRS both before and after weight reduction were included in the analysis. Their body weight decreased from 78.02 ± 10.89 kg to 72.36 ± 10.38 kg over a mean of 71.74 ± 58.11 days. FLI, HSI, and MRS values decreased significantly from 41.52 ± 19.05 to 24.53 ± 15.93, 39.64 ± 3.74 to 35.06 ± 3.82, and 12.20 ± 4.05 to 6.24 ± 3.36, respectively. No significant decreases in NFS were observed. There was a significant correlation between the extent of HSI change and the extent of MRS change (R value = 0.69, < 0.001), although there was no correlation between MRS and FLI.

Conclusion: The weight reduction program significantly improved non-invasive indices of hepatic steatosis over a short period. HSI may allow for prediction of simple decreases in hepatic steatosis.

Citing Articles

Multivariable linear model for predicting graft weight based on 3-dimensional volumetry in regards to body weight change of living liver donor: an observational cohort study.

Han S, Rhu J, Lim S, Choi G, Kim J, Joh J Ann Surg Treat Res. 2024; 107(2):91-99.

PMID: 39139829 PMC: 11317358. DOI: 10.4174/astr.2024.107.2.91.

Assessing the clinical utility of major indices for nonalcoholic fatty liver disease in East Asian populations.

Hang Y, Lee C, Roman Y Biomark Med. 2023; 17(8):445-454.

PMID: 37449859 PMC: 10463214. DOI: 10.2217/bmm-2023-0172.

References

Kim H, Lee K, Lee K, Yi N, Lee H, Hong G . Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014; 28(5):521-9. DOI: 10.1111/ctr.12343. View

Nugroho A, Kim O, Lee K, Song S, Kim H, Hong S . Evaluation of donor workups and exclusions in a single-center experience of living donor liver transplantation. Liver Transpl. 2017; 23(5):614-624. DOI: 10.1002/lt.24762. View

Khang A, Lee H, Yi D, Kang Y, Son S . The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010-2011. Diabetes Metab Syndr Obes. 2019; 12:181-190. PMC: 6353218. DOI: 10.2147/DMSO.S189544. View

Farrell G, Wong V, Chitturi S . NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5):307-18. DOI: 10.1038/nrgastro.2013.34. View

Sviklane L, Olmane E, Dzerve Z, Kupcs K, Pirags V, Sokolovska J . Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol. 2017; 33(1):270-276. DOI: 10.1111/jgh.13814. View

Doyle A, Adeyi O, Khalili K, Fischer S, Dib M, Goldaracena N . Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation. Liver Transpl. 2016; 22(9):1295-300. DOI: 10.1002/lt.24495. View

Nakamuta M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takasugi S . Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation. 2005; 80(5):608-12. DOI: 10.1097/01.tp.0000166009.77444.f3. View

Jeong E, Won Jun D, Cho Y, Choe Y, Ryu S, Lee S . Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol. 2013; 19(3):266-72. PMC: 3796676. DOI: 10.3350/cmh.2013.19.3.266. View

Chabanova E, Bille D, Thisted E, Holm J, Thomsen H . (1)H MRS assessment of hepatic steatosis in overweight children and adolescents: comparison between 3T and open 1T MR-systems. Abdom Imaging. 2012; 38(2):315-9. DOI: 10.1007/s00261-012-9930-2. View

10.

Mattar S, Velcu L, Rabinovitz M, Demetris A, Krasinskas A, Barinas-Mitchell E . Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005; 242(4):610-7. PMC: 1402345. DOI: 10.1097/01.sla.0000179652.07502.3f. View

11.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMC: 1636651. DOI: 10.1186/1471-230X-6-33. View

12.

Kahl S, Strassburger K, Nowotny B, Livingstone R, Kluppelholz B, Kessel K . Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One. 2014; 9(4):e94059. PMC: 3986069. DOI: 10.1371/journal.pone.0094059. View

13.

Won Jun D, Kim S, Park S, Jin S, Lee J, Lee J . External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol. 2016; 32(5):1094-1099. DOI: 10.1111/jgh.13648. View

14.

Bonekamp S, Kamel I, Solga S, Clark J . Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. J Hepatol. 2008; 50(1):17-35. DOI: 10.1016/j.jhep.2008.10.016. View

15.

Hwang I, Lee J, Lee K, Yoon J, Kiefer B, Han J . Hepatic steatosis in living liver donor candidates: preoperative assessment by using breath-hold triple-echo MR imaging and 1H MR spectroscopy. Radiology. 2014; 271(3):730-8. DOI: 10.1148/radiol.14130863. View

16.

Koehler E, Schouten J, Hansen B, Hofman A, Stricker B, Janssen H . External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013; 11(9):1201-4. DOI: 10.1016/j.cgh.2012.12.031. View

17.

Williams C, Stengel J, Asike M, Torres D, Shaw J, Contreras M . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2010; 140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038. View

18.

Treeprasertsuk S, Bjornsson E, Enders F, Suwanwalaikorn S, Lindor K . NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013; 19(8):1219-29. PMC: 3587478. DOI: 10.3748/wjg.v19.i8.1219. View

19.

Lee J, Kim K, Lee S, Yu E, Lim Y, Lee H . Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007; 47(2):239-44. DOI: 10.1016/j.jhep.2007.02.007. View

20.

Liu Y, Liu S, Huang J, Zhu Y, Lin S . Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study. J Gastroenterol Hepatol. 2022; 37(5):938-945. DOI: 10.1111/jgh.15799. View